Measuring impact of benign thyroid diseases on quality of life

Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiForskningfagfællebedømt

Standard

Measuring impact of benign thyroid diseases on quality of life. / Watt, Torquil.

Encyclopedia of Endocrine Diseases. Elsevier, 2018. s. 802-812.

Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiForskningfagfællebedømt

Harvard

Watt, T 2018, Measuring impact of benign thyroid diseases on quality of life. i Encyclopedia of Endocrine Diseases. Elsevier, s. 802-812. https://doi.org/10.1016/B978-0-12-801238-3.64960-7

APA

Watt, T. (2018). Measuring impact of benign thyroid diseases on quality of life. I Encyclopedia of Endocrine Diseases (s. 802-812). Elsevier. https://doi.org/10.1016/B978-0-12-801238-3.64960-7

Vancouver

Watt T. Measuring impact of benign thyroid diseases on quality of life. I Encyclopedia of Endocrine Diseases. Elsevier. 2018. s. 802-812 https://doi.org/10.1016/B978-0-12-801238-3.64960-7

Author

Watt, Torquil. / Measuring impact of benign thyroid diseases on quality of life. Encyclopedia of Endocrine Diseases. Elsevier, 2018. s. 802-812

Bibtex

@inbook{3582e15335524aef8ace59ef1035897c,
title = "Measuring impact of benign thyroid diseases on quality of life",
abstract = "Quality of life (QoL), defined as “the subjective assessment of the impact of disease and its treatment across the physical, psychological, social, and somatic domains of functioning and well-being,” is measured by patient-reported outcomes, abbreviated PRO. PROs may be generic or disease specific. This article focuses on the latter, by reviewing existing thyroid-specific QoL measures or “PROs.” Thirteen instruments were reviewed, characterized and had their measurement properties evaluated. Eight of these were developed in accordance with current standards: Three instruments for patients with Graves{\textquoteright} orbitopathy: Graves{\textquoteright} orbitopathy quality of life instrument (GO-QOL), Graves{\textquoteright} ophthalmopathy quality of life scale (GO-QLS) and Thyroid eye disease quality of life scale (TED-QOL) and one triplet of instruments for patients with hypothyroidism, Underactive thyroid-dependent quality of life questionnaire (ThyDQoL), Thyroid symptom rating questionnaire (ThySRQ) and Thyroid treatment satisfaction questionnaire (ThyTSQ) and Thyroid-related patient reported outcome (ThyPRO/ThyPRO-39 (short-form)), for patients with any benign thyroid disease, and thus the only PRO validated for use among patients with non-toxic goiter and hyperthyroidism.",
keywords = "Health-related quality of life, Patient-reported outcomes, Quality of life measurement, Well-being",
author = "Torquil Watt",
note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2018",
doi = "10.1016/B978-0-12-801238-3.64960-7",
language = "English",
isbn = "9780128121993",
pages = "802--812",
booktitle = "Encyclopedia of Endocrine Diseases",
publisher = "Elsevier",
address = "Netherlands",

}

RIS

TY - CHAP

T1 - Measuring impact of benign thyroid diseases on quality of life

AU - Watt, Torquil

N1 - Publisher Copyright: © 2019 Elsevier Inc.

PY - 2018

Y1 - 2018

N2 - Quality of life (QoL), defined as “the subjective assessment of the impact of disease and its treatment across the physical, psychological, social, and somatic domains of functioning and well-being,” is measured by patient-reported outcomes, abbreviated PRO. PROs may be generic or disease specific. This article focuses on the latter, by reviewing existing thyroid-specific QoL measures or “PROs.” Thirteen instruments were reviewed, characterized and had their measurement properties evaluated. Eight of these were developed in accordance with current standards: Three instruments for patients with Graves’ orbitopathy: Graves’ orbitopathy quality of life instrument (GO-QOL), Graves’ ophthalmopathy quality of life scale (GO-QLS) and Thyroid eye disease quality of life scale (TED-QOL) and one triplet of instruments for patients with hypothyroidism, Underactive thyroid-dependent quality of life questionnaire (ThyDQoL), Thyroid symptom rating questionnaire (ThySRQ) and Thyroid treatment satisfaction questionnaire (ThyTSQ) and Thyroid-related patient reported outcome (ThyPRO/ThyPRO-39 (short-form)), for patients with any benign thyroid disease, and thus the only PRO validated for use among patients with non-toxic goiter and hyperthyroidism.

AB - Quality of life (QoL), defined as “the subjective assessment of the impact of disease and its treatment across the physical, psychological, social, and somatic domains of functioning and well-being,” is measured by patient-reported outcomes, abbreviated PRO. PROs may be generic or disease specific. This article focuses on the latter, by reviewing existing thyroid-specific QoL measures or “PROs.” Thirteen instruments were reviewed, characterized and had their measurement properties evaluated. Eight of these were developed in accordance with current standards: Three instruments for patients with Graves’ orbitopathy: Graves’ orbitopathy quality of life instrument (GO-QOL), Graves’ ophthalmopathy quality of life scale (GO-QLS) and Thyroid eye disease quality of life scale (TED-QOL) and one triplet of instruments for patients with hypothyroidism, Underactive thyroid-dependent quality of life questionnaire (ThyDQoL), Thyroid symptom rating questionnaire (ThySRQ) and Thyroid treatment satisfaction questionnaire (ThyTSQ) and Thyroid-related patient reported outcome (ThyPRO/ThyPRO-39 (short-form)), for patients with any benign thyroid disease, and thus the only PRO validated for use among patients with non-toxic goiter and hyperthyroidism.

KW - Health-related quality of life

KW - Patient-reported outcomes

KW - Quality of life measurement

KW - Well-being

U2 - 10.1016/B978-0-12-801238-3.64960-7

DO - 10.1016/B978-0-12-801238-3.64960-7

M3 - Book chapter

AN - SCOPUS:85079264773

SN - 9780128121993

SP - 802

EP - 812

BT - Encyclopedia of Endocrine Diseases

PB - Elsevier

ER -

ID: 303679210